Advertisement

Mosunetuzumab for Relapsed or Refractory Aggressive and Indolent B-Cell Non-Hodgkin Lymphomas
Posted: 02/10/2022 | By: Matthew Stenger

Question 1 of 5

Complete response rates were:

Choose 1

A
48.5% among all patients
B
19.4% among those with aggressive disease and 48.5% among those with indolent disease
C
34.9% among those with aggressive disease and 48.5% among those with indolent disease
D
34.9% among all patients

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage